Explore stories from Atlantic Canada.
Subject of emergency alert message arrested - May 2, 2024 | SaltWire #dartmouth #update #suspect - Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its experimental obesity drug.
Novo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the day.Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide, which, if approved, would compete Novo's Wegovy and Eli Lilly's Zepbound.
"Novo's share price today is certainly factoring in some negative reaction to Amgen's positive commentary on MariTide development yesterday," Kepler Cheuvreux analyst David Evans said, but added that"a continued negative reaction to results and pricing concerns yesterday is likely also a smaller part of the move today".
Amgen did not provide any specifics on the actual data of its trial, but competition is heating up in a market estimated to be worth as much as $100 billion by the end of the decade, in which Novo Nordisk has the lead for now.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Slides as Amgen Update Fuels Obesity Drug Competition FearsNovo Nordisk A/S shares slid on Friday as a US rival’s comments on an experimental obesity drug gave rise to concerns about potential new competition in the rapidly growing space.
Read more »
Novo Slides as Amgen Update Fuels Obesity Drug Competition Fears(Bloomberg) -- Novo Nordisk A/S shares slid on Friday as a US rival’s comments on an experimental obesity drug gave rise to concerns about potential new...
Read more »
Novo Nordisk slides while Moderna pops: Tale of two pharma stocksPharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall...
Read more »
Novo Nordisk owner to invest $200 million in quantum computing startupsExplore stories from Atlantic Canada.
Read more »
Ozempic Subsidies Cut in Novo Nordisk’s Home Country of DenmarkSubsidies for Ozempic will be restricted in Novo Nordisk A/S’s home country of Denmark due to rising public spending on the blockbuster diabetes medicine, which is increasingly being used as a weight-loss treatment.
Read more »
Novo Nordisk raises 2024 outlook as company races to boost output of Wegovy weight-loss drugNovo Nordisk reported better-than-expected first-quarter profits on Thursday as it looks to fend off competition from rival Eli Lilly
Read more »